Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L

被引:63
作者
Calmels, B
Paul, S
Futin, N
Ledoux, C
Stoeckel, F
Acres, B
机构
[1] Transgene SA, Mol Immunol Lab, F-67082 Strasbourg, France
[2] Transgene SA, Anim Facil, F-67082 Strasbourg, France
[3] Transgene SA, Adenovirol Lab, F-67082 Strasbourg, France
[4] Transgene SA, Immunohistochem Lab, F-67082 Strasbourg, France
[5] Transgene SA, Div Med & Regulatory Affairs, F-67082 Strasbourg, France
关键词
GITR; tumor immunity; tolerance; T-cell activation;
D O I
10.1038/sj.cgt.7700781
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recent evidence has resurrected the concept of specialized populations of T lymphocytes that are able to suppress an antigen-specific immune response. T-regulatory cells (T-reg) have been characterized as CD4+ CD25+ T cells. Previous reports describing differential gene expression analysis have shown that the glucocorticoid-induced tumor necrosis family receptor family-related gene ( GITR) is upregulated in these cells. Furthermore, antibodies specific for GITR have been shown to inhibit the T-suppressor function of CD4+ CD25+ T-reg. The ligands for both mouse and human GITR have been cloned recently. We have inserted the sequences for natural, membrane-bound GITR-ligand (GITR-L) and a truncated secreted form of GITR-L (GITR-Lsol) into the adenovirus-5 genome. Coculture experiments show that cells infected with Ad-GITR-L and supernatants from cells infected with Ad-GITR-Lsol can increase the proliferation of both CD4+ CD25- and CD8+ T cells in response to anti-CD3 stimulation, in the presence, as well as in the absence, of CD4+ CD25+ T cells. The virus constructs were injected into growing B16 melanoma tumors. Ad-GITR-L was shown to attract infiltration with both CD4+ and CD8+ T cells. Both constructs were shown to inhibit tumor growth.
引用
收藏
页码:198 / 205
页数:8
相关论文
共 21 条
[1]   IMMUNE-RESPONSES IN HUMANS WHILE RECEIVING ADOPTIVE IMMUNOTHERAPY WITH RECOMBINANT INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS - ACUTE ANERGY TO MITOGENS AND RECALL ANTIGENS [J].
ADES, EW ;
BOSSE, D ;
ORR, S ;
GILLESPIE, T .
PATHOBIOLOGY, 1990, 58 (02) :78-83
[2]   Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine [J].
Berd, D ;
Sato, T ;
Maguire, HC ;
Kairys, J ;
Mastrangelo, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :403-415
[3]  
BERD D, 1984, CANCER RES, V44, P1275
[4]   Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli [J].
Chartier, C ;
Degryse, E ;
Gantzer, M ;
Dieterle, A ;
Pavirani, A ;
Mehtali, M .
JOURNAL OF VIROLOGY, 1996, 70 (07) :4805-4810
[5]   ANTIGEN-DRIVEN AND RECEPTOR-DRIVEN REGULATORY MECHANISMS .7. H-2-RESTRICTED ANTI-IDIOTYPIC SUPPRESSOR FACTOR FROM EFFERENT SUPPRESSOR T-CELLS [J].
DIETZ, MH ;
SY, MS ;
BENACERRAF, B ;
NISONOFF, A ;
GREENE, MI ;
GERMAIN, RN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 153 (02) :450-463
[6]  
Erbs P, 2000, CANCER RES, V60, P3813
[7]   New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses [J].
Fallaux, FJ ;
Bout, A ;
Van der Velde, I ;
Van den Wollenberg, DJM ;
Hehir, KM ;
Keegan, J ;
Auger, C ;
Cramer, SJ ;
Van Ormondt, H ;
Van der Eb, AJ ;
Valerio, D ;
Hoeben, RC .
HUMAN GENE THERAPY, 1998, 9 (13) :1909-1917
[8]  
GERSHON RK, 1970, IMMUNOLOGY, V18, P723
[9]   CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative [J].
Ghiringhelli, F ;
Larmonier, N ;
Schmitt, E ;
Parcellier, A ;
Cathelin, D ;
Garrido, C ;
Chauffert, B ;
Solary, E ;
Bonnotte, B ;
Martin, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (02) :336-344
[10]   Cutting edge:: The natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression [J].
Ji, HB ;
Liao, GX ;
Faubion, WA ;
Abadía-Molina, AC ;
Cozzo, C ;
Laroux, FS ;
Caton, A ;
Terhorst, C .
JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :5823-5827